165 related articles for article (PubMed ID: 36032811)
1. Recurrent uterine inflammatory myofibroblastic tumor previously managed as leiomyosarcoma has sustained response to alectinib.
Carballo EV; Pham TV; Turashvili G; Hanley K; Starbuck KD; Meisel JL
Gynecol Oncol Rep; 2022 Oct; 43():101062. PubMed ID: 36032811
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory myofibroblastic tumor of the uterus - case report.
Štiková Z; Ptáková N; Horáková M; Kosťun J; Ondič O
Cesk Patol; 2019; 55(4):239-243. PubMed ID: 31842556
[TBL] [Abstract][Full Text] [Related]
3. Case Report: Clinical response to anaplastic lymphoma kinase inhibitor-based targeted therapy in uterine inflammatory myofibroblastic tumor harboring
Zhao T; Zhang X; Liu X; Ren M; Cheng Y; Wang J; Luo Z
Front Oncol; 2023; 13():1147974. PubMed ID: 37035208
[TBL] [Abstract][Full Text] [Related]
4. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.
Honda K; Kadowaki S; Kato K; Hanai N; Hasegawa Y; Yatabe Y; Muro K
Invest New Drugs; 2019 Aug; 37(4):791-795. PubMed ID: 30790150
[TBL] [Abstract][Full Text] [Related]
5. TNS1-ALK Fusion in a Recurrent, Metastatic Uterine Mesenchymal Tumor Originally Diagnosed as Leiomyosarcoma.
Lee J; Singh A; Ali SM; Lin DI; Klempner SJ
Acta Med Acad; 2019 Apr; 48(1):116-120. PubMed ID: 31264439
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical and selected genetic reflex testing of all uterine leiomyosarcomas and STUMPs for ALK gene rearrangement may provide an effective screening tool in identifying uterine ALK-rearranged mesenchymal tumors.
Ptáková N; Miesbauerová M; Kosťun J; Grossmann P; Šidlová H; Pavelka J; Presl J; Alaghehbandan R; Bouda J; Ondič O
Virchows Arch; 2018 Nov; 473(5):583-590. PubMed ID: 30116888
[TBL] [Abstract][Full Text] [Related]
7. Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring
Wang Z; Geng Y; Yuan LY; Wang MM; Ye CY; Sun L; Dai WP; Zang YS
Front Oncol; 2022; 12():761558. PubMed ID: 35237506
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib.
Sunga CGG; Higgins MS; Ricciotti RW; Liu YJ; Cranmer LD
Cancer Rep (Hoboken); 2023 Mar; 6(3):e1792. PubMed ID: 36754839
[TBL] [Abstract][Full Text] [Related]
9. STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion.
Subbiah V; McMahon C; Patel S; Zinner R; Silva EG; Elvin JA; Subbiah IM; Ohaji C; Ganeshan DM; Anand D; Levenback CF; Berry J; Brennan T; Chmielecki J; Chalmers ZR; Mayfield J; Miller VA; Stephens PJ; Ross JS; Ali SM
J Hematol Oncol; 2015 Jun; 8():66. PubMed ID: 26062823
[TBL] [Abstract][Full Text] [Related]
10. Uterine Inflammatory Myofibroblastic Neoplasms With Aggressive Behavior, Including an Epithelioid Inflammatory Myofibroblastic Sarcoma: A Clinicopathologic Study of 9 Cases.
Collins K; Ramalingam P; Euscher ED; Reques Llanos A; García A; Malpica A
Am J Surg Pathol; 2022 Jan; 46(1):105-117. PubMed ID: 34138797
[TBL] [Abstract][Full Text] [Related]
11. Pediatric inflammatory myofibroblastic tumor of the bladder with ALK-FN1 fusion successfully treated by alectinib.
Fujiki T; Sakai Y; Ikawa Y; Takenaka M; Noguchi K; Kuroda R; Abe T; Nomura K; Sakai S; Wada T
Pediatr Blood Cancer; 2023 Apr; 70(4):e30172. PubMed ID: 36635892
[TBL] [Abstract][Full Text] [Related]
12. Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib.
Testa S; Million L; Longacre T; Bui N
Case Rep Oncol; 2021; 14(2):812-819. PubMed ID: 34248545
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory myofibroblastic tumor of the uterus: a clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors.
Rabban JT; Zaloudek CJ; Shekitka KM; Tavassoli FA
Am J Surg Pathol; 2005 Oct; 29(10):1348-55. PubMed ID: 16160478
[TBL] [Abstract][Full Text] [Related]
14. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Parker BM; Parker JV; Lymperopoulos A; Konda V
J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
[TBL] [Abstract][Full Text] [Related]
15. Histopathologic and Molecular Characterization of Uterine Leiomyoma-like Inflammatory Myofibroblastic Tumor: Comparison to Molecular Subtypes of Uterine Leiomyoma.
Kuisma H; Jokinen V; Pasanen A; Heikinheimo O; Karhu A; Välimäki N; Aaltonen L; Bützow R
Am J Surg Pathol; 2022 Aug; 46(8):1126-1136. PubMed ID: 35426837
[TBL] [Abstract][Full Text] [Related]
16. ALK Is a Specific Diagnostic Marker for Inflammatory Myofibroblastic Tumor of the Uterus.
Mohammad N; Haimes JD; Mishkin S; Kudlow BA; Leong MY; Chew SH; Koay E; Whitehouse A; Cope N; Ali RH; Köbel M; Stewart CJR; McCluggage WG; Lee CH
Am J Surg Pathol; 2018 Oct; 42(10):1353-1359. PubMed ID: 30015720
[TBL] [Abstract][Full Text] [Related]
17. Uterine mesenchymal tumors harboring
Kyi C; Friedman CF; Mueller JJ; Benayed R; Ladanyi M; Arcila M; Yang SR; Hensley ML; Chiang S
Gynecol Oncol Rep; 2021 Aug; 37():100852. PubMed ID: 34522753
[TBL] [Abstract][Full Text] [Related]
18. Uterine Inflammatory Myofibroblastic Tumors Frequently Harbor ALK Fusions With IGFBP5 and THBS1.
Haimes JD; Stewart CJR; Kudlow BA; Culver BP; Meng B; Koay E; Whitehouse A; Cope N; Lee JC; Ng T; McCluggage WG; Lee CH
Am J Surg Pathol; 2017 Jun; 41(6):773-780. PubMed ID: 28490045
[TBL] [Abstract][Full Text] [Related]
19. Case Report: Early Distant Metastatic Inflammatory Myofibroblastic Tumor Harboring
Han Q; He X; Cui L; Qiu Y; Li Y; Chen H; Zhang H
Front Med (Lausanne); 2022; 9():826705. PubMed ID: 35280868
[TBL] [Abstract][Full Text] [Related]
20. Impact of ALK Inhibitors in Patients With
Takeyasu Y; Okuma HS; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Shimoi T; Noguchi E; Arakawa A; Mori T; Sunami K; Kubo T; Kohno T; Akihiko Y; Yamamoto N; Yonemori K
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
